[HTML][HTML] Small cell lung cancer: can recent advances in biology and molecular biology be translated into improved outcomes?
Small cell lung cancer (SCLC) is one of the four major histological types of lung cancer. The
incidence of SCLC in developed countries has declined in recent years, presumably …
incidence of SCLC in developed countries has declined in recent years, presumably …
[HTML][HTML] Small cell lung cancer (SCLC): no treatment advances in recent years
F Koinis, A Kotsakis, V Georgoulias - Translational lung cancer …, 2016 - ncbi.nlm.nih.gov
Small cell lung cancer (SCLC) is an aggressive malignancy with a distinct natural history
and dismal prognosis. Given its predisposition for early dissemination, patients are …
and dismal prognosis. Given its predisposition for early dissemination, patients are …
Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung …
K Goto, Y Ohe, T Shibata, T Seto, T Takahashi… - The Lancet …, 2016 - thelancet.com
Background Etoposide and irinotecan are key drugs in the treatment of small-cell lung
cancer. We did this study to investigate whether combined chemotherapy with cisplatin …
cancer. We did this study to investigate whether combined chemotherapy with cisplatin …
[图书][B] Physicians' Cancer Chemotherapy Drug Manual 2017
E Chu - 2016 - books.google.com
Written by world-class experts in clinical cancer therapeutics, Physicians' Cancer
Chemotherapy Drug Manual 2017 provides a complete, easy-to-use catalog of over 100 …
Chemotherapy Drug Manual 2017 provides a complete, easy-to-use catalog of over 100 …
Trends, predictors, and impact of systemic chemotherapy in small cell lung cancer patients between 1985 and 2005
BACKGROUND The last 3 decades have witnessed limited therapeutic advances in small
cell lung cancer (SCLC) management. This study evaluated real‐world trends in the use of …
cell lung cancer (SCLC) management. This study evaluated real‐world trends in the use of …
[HTML][HTML] A phase II study of nintedanib in patients with relapsed small cell lung cancer
JY Han, HY Kim, KY Lim, B Hwangbo, JS Lee - Lung Cancer, 2016 - Elsevier
Objectives Nintedanib is an oral triple angiokinase inhibitor. This study was conducted to
evaluate the efficacy and safety of nintedanib in patients (pts) with relapsed/refractory small …
evaluate the efficacy and safety of nintedanib in patients (pts) with relapsed/refractory small …
[HTML][HTML] A phase II study of weekly paclitaxel plus gemcitabine as a second-line therapy in patients with metastatic or recurrent small cell lung cancer
T Yun, HT Kim, JY Han, SJ Yoon, HY Kim… - Cancer Research and …, 2016 - ncbi.nlm.nih.gov
Purpose Paclitaxel (P) and gemcitabine (G) are clinically synergistic in small cell lung
cancer (SCLC). We evaluated the efficacy of PG as a salvage treatment for SCLC patients …
cancer (SCLC). We evaluated the efficacy of PG as a salvage treatment for SCLC patients …
[PDF][PDF] Role of CD15 and CD15s in the Cellular Mechanisms of Cancer Cell Metastasis from Lung to the Brain
SA Jassam - 2016 - researchgate.net
Role of CD15 and CD15s in the Cellular Mechanisms of Cancer Cell Metastasis from Lung to
the Brain Page 1 1 Role of CD15 and CD15s in the Cellular Mechanisms of Cancer Cell …
the Brain Page 1 1 Role of CD15 and CD15s in the Cellular Mechanisms of Cancer Cell …
伊力替康联合顺铂与拓扑替康二线治疗小细胞肺癌疗效比较
郝建东， 李娟， 葛鹏飞 - 山西医药杂志, 2016 - cqvip.com
小细胞肺癌(small cell lung cancer, SCLC) 是一种高侵袭性肿瘤, 生长迅速,
早期即可发生远处转移, 预后差. 目前报道, 局限期SCLC 的中位生存时间(median survival time …
早期即可发生远处转移, 预后差. 目前报道, 局限期SCLC 的中位生存时间(median survival time …
[PDF][PDF] Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas
MH Rubinstein, G Melillo, Y Pommier, W Bonner… - academia.edu
ABSTRACT A phase I trial of ABT-888 (veliparib), a poly (ADP-ribose) polymerase (PARP
inhibitor), in combination with topotecan, a topoisomerase I–targeted agent, was performed …
inhibitor), in combination with topotecan, a topoisomerase I–targeted agent, was performed …